Keywords : CML
A Study Of Thyroid Dysfunction Caused By Tyrosine Kinase Inhibitors In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 8, Pages 3611-3616
Background –Tyrosine kinase inhibitors (TKI) are used as the frontline drugs in the management of patients with chronic myeloid leukemia (CML). The aim of the study was to find the effect of tyrosine kinase inhibitors on thyroid function in patients with Philadelphia chromosome positive CML.
Materials & Methods – A retrospective observational study was conducted in 100 patients attending the hematology OPD of a tertiary care hospital. Pre and post treatment thyroid profile were done for all the patients and the effect of TKI on thyroid profile was assessed.
Results – There was a male predominance (79%) in the study population. 64% of the patients were in the age group of 41 to 60 years. There was statistically significant raise in the serum TSH and fall in the T3 and T4 values after the completion of treatment of 6 months (P < 0.00001). At the end of 6-month yyytreatment period, 9% of patients had overt hypothyroidism, 6% of patients had subclinical hypothyroidism and the remaining were euthyroid. (P = 0.0042)
Conclusion – The presence of statistically significant increase in the TSH levels and the increase in presence of thyroid dysfunction makes it vital to screen for thyroid abnormalities in patients with CML. Especially in patients with subclinical hypothyroidism, strict regular follow up is recommended to prevent overt hypothyroidism in them.